Accumulating evidence suggests that many cytotoxic signals occurring in the neurodegenerative brain can initiate neuronal death processes, including oxidative stress, inflammation, and accumulation of iron at the sites of the neuronal deterioration. Neuroprotection by iron chelators has been widely recognized with respect to their ability to prevent hydroxyl radical formation in the Fenton reaction by sequestering redox-active iron. An additional neuroprotective mechanism of iron chelators is associated with their ability to upregulate or stabilize the transcriptional activator, hypoxia-inducible factor-1α (HIF-1α). HIF-1α stability within the cells is under the control of a class of iron-dependent and oxygen-sensor enzymes, HIF prolyl-4-hydroxylases (PHDs) that target HIF-1α for degradation. Thus, an emerging novel target for neuroprotection is associated with the HIF system to promote stabilization of HIF-1α and increase transcription of HIF-1–related survival genes, which have been reported to be regulated in patient's brains afflicted with diverse neurodegenerative diseases. In accordance, a new potential therapeutic strategy for neurodegenerative diseases is explored, by which iron chelators would inhibit PHDs, target the HIF-1–signaling pathway and ultimately activate HIF-1–dependent neuroprotective genes. This review discusses two interrelated approaches concerning therapy targets in neurodegeneration, sharing in common the implementation of iron chelation activity: antioxidation and HIF-1–pathway activation. Antioxid. Redox Signal. 13, 919–949.
AdlardPA, ChernyRA, FinkelsteinDI, GautierE, RobbE, CortesM, VolitakisI, LiuX, SmithJP, PerezK, LaughtonK, LiQX, CharmanSA, NicolazzoJA, WilkinsS, DelevaK, LynchT, KokG, RitchieCW, TanziRE, CappaiR, MastersCL, BarnhamKJ, BushAI. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron, 59:43–55. 2008.
2.
AkaoY, MaruyamaW, ShimizuS, YiH, NakagawaY, Shamoto-NagaiM, YoudimMBH, TsujimotoY, NaoiM. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem, 82:913–923. 2002.
3.
AlmliLM, HamrickSE, KoshyAA, TauberMG, FerrieroDM. Multiple pathways of neuroprotection against oxidative stress and excitotoxic injury in immature primary hippocampal neurons. Brain Res Dev Brain Res, 132:121–129. 2001.
4.
AltamuraS, MuckenthalerMU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis, 16:879–895. 2009.
5.
AminovaLR, ChavezJC, LeeJ, RyuH, KungA, LamannaJC, RatanRR. Prosurvival and prodeath effects of hypoxia-inducible factor-1alpha stabilization in a murine hippocampal cell line. J Biol Chem, 280:3996–4003. 2005.
6.
AminovaLR, SiddiqA, RatanRR. Antioxidants, HIF prolyl hydroxylase inhibitors or short interfering RNAs to BNIP3 or PUMA, can prevent prodeath effects of the transcriptional activator, HIF-1alpha, in a mouse hippocampal neuronal line. Antioxid Redox Signal, 10:1989–1998. 2008.
7.
AtamnaH, FreyWH2nd. A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. Proc Natl Acad Sci U S A, 101:11153–11158. 2004.
8.
AtwoodCS, ScarpaRC, HuangX, MoirRD, JonesWD, FairlieDP, TanziRE, BushAI. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem, 75:1219–1233. 2000.
9.
Avramovich-TiroshY, AmitT, Bar-AmO, ZhengH, FridkinM, YoudimMB. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem, 100:490–502. 2006.
10.
Avramovich-TiroshY, Bar-AmO, AmitT, YoudimMBH, WeinrebO. Up-regulation of hypoxia-inducible factor (HIF)-1 alpha and HIF-regulated genes in cortical neurons by the novel anti-Alzheimer multifunctional iron chelator drugs. Curr Alzheimer Res, 2009Dec31[Epub ahead of print].
11.
Avramovich-TiroshY, ReznichenkoL, MitT, ZhengH, FridkinM, WeinrebO, MandelS, YoudimMB. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res, 4:403–411. 2007.
12.
BabySM, RoyA, MokashiAM, LahiriS. Effects of hypoxia and intracellular iron chelation on hypoxia-inducible factor-1alpha and -1beta in the rat carotid body and glomus cells. Histochem Cell Biol, 120:343–352. 2003.
13.
BandyopadhyayS, HuangX, ChoH, GreigNH, YoudimMB, RogersJT. Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator. J Neural Transmission Suppl, 71:237–247. 2006.
14.
BanerjeeA, KunwarA, MishraB, PriyadarsiniKI. Concentration dependent antioxidant/pro-oxidant activity of curcumin studies from AAPH induced hemolysis of RBCs. Chem Biol Interact, 174:134–139. 2008.
15.
Bar-AmO, AmitT, YoudimMB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem, 103:500–508. 2007.
16.
Bar-AmO, WeinrebO, AmitA, YoudimMBH. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem, 112:1131–1137. 2010.
17.
Bar-AmO, WeinrebO, AmitT, YoudimMB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J, 19:1899–1901. 2005.
18.
BartzokisG, SultzerD, CummingsJ, HoltLE, HanceDB, HendersonVW, MintzJ. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry, 57:47–53. 2000.
19.
Ben-ShacharD, EshelG, FinbergJP, YoudimMB. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem, 56:1441–1444. 1991.
20.
Ben-ShacharD, EshelG, RiedererP, YoudimMBH. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Ann Neurol, 32,suppl:S105–S110. 1992.
21.
Ben-ShacharD, KahanaN, KampelV, WarshawskyA, YoudimMBH. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology, 46:254–263. 2004.
22.
Ben-ShacharD, YoudimMB. Intranigral iron injection induces behavioral and biochemical “parkinsonism” in rats. J Neurochem, 57:2133–2135. 1991.
23.
BenarrochEE. Brain iron homeostasis and neurodegenerative disease. Neurology, 72:1436–1440. 2009.
24.
BergD, GerlachM, YoudimMB, DoubleKL, ZeccaL, RiedererP, BeckerG. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem, 79:225–236. 2001.
25.
BergeronM, GiddayJM, YuAY, SemenzaGL, FerrieroDM, SharpFR. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain. Ann Neurol, 48:285–296. 2000.
26.
BergeronM, YuAY, SolwayKE, SemenzaGL, SharpFR. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci, 11:4159–4170. 1999.
27.
BernaudinM, NedelecAS, DivouxD, MacKenzieET, PetitE, Schumann-BardP. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab, 22:393–403. 2002.
28.
BernaudinM, SharpFR. Methods to detect hypoxia-induced ischemic tolerance in the brain. Methods Enzymol, 381:399–416. 2004.
29.
BernhardtWM, WarneckeC, WillamC, TanakaT, WiesenerMS, EckardtKU. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol, 435:221–245. 2007.
30.
BerraE, BenizriE, GinouvesA, VolmatV, RouxD, PouyssegurJ. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J, 22:4082–4090. 2003.
31.
BharathS, HsuM, KaurD, RajagopalanS, AndersenJK. Glutathione, iron and Parkinson's disease. Biochem Pharmacol, 64:1037–1048. 2002.
32.
BianchiL, TacchiniL, CairoG. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res, 27:4223–4227. 1999.
33.
BirkmayerW, RiedererP, AmbroziL, YoudimMBH. Implications of combined treatment with “Madopar” and L-deprenil in Parkinson's disease: a long-term study. Lancet, 1:439–443. 1977.
34.
BologninS, DragoD, MessoriL, ZattaP. Chelation therapy for neurodegenerative diseases. Med Res Rev, 29:547–570. 2009.
35.
BraakH, Del TrediciK. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging, 25:19–23. 2004.
36.
BruickRK. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev, 17:2614–2623. 2003.
37.
BrunA, EnglundE. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol, 19:253–262. 1986.
38.
BullockR. Future directions in the treatment of Alzheimer's disease. Expert Opin Invest Drugs, 13:303–314. 2004.
39.
BushAI. The metallobiology of Alzheimer's disease. Trends Neurosci, 26:207–214. 2003.
40.
BushAI. Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis, 15:223–240. 2008.
41.
CahoonL. The curious case of clioquinol. Nat Med, 15:356–359. 2009.
42.
CarmelietP, StorkebaumE. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol, 13:39–53. 2002.
43.
CarrilloMC, KitaniK, KanaiS, SatoY, MiyasakaK, IvyGO. (-)Deprenyl increases activities of superoxide dismutase and catalase in certain brain regions in old male mice. Life Sci, 54:975–981. 1994.
44.
CarrilloMC, MinamiC, KitaniK, MaruyamaW, OhashiK, YamamotoT, NaoiM, KanaiS, YoudimMBH. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci, 67:577–585. 2000.
45.
CastellaniRJ, HondaK, ZhuX, CashAD, NunomuraA, PerryG, SmithMA. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev, 3:319–326. 2004.
46.
CastellaniRJ, MoreiraPI, LiuG, DobsonJ, PerryG, SmithMA, ZhuX. Iron: the redox-active center of oxidative stress in Alzheimer disease. Neurochem Res, 32:1640–1645. 2007.
47.
ChanDA, KawaharaTL, SutphinPD, ChangHY, ChiJT, GiacciaAJ. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell, 15:527–538. 2009.
48.
ChavezJC, LaMannaJC. Hypoxia-inducible factor-1alpha accumulation in the rat brain in response to hypoxia and ischemia is attenuated during aging. Adv Exp Med Biol, 510:337–341. 2003.
49.
CheahJH, KimSF, HesterLD, ClancyKW, PattersonSE3rd, PapadopoulosV, SnyderSH. NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron, 51:431–440. 2006.
50.
ChenC, YuR, OwuorED, KongAN. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res, 23:605–612. 2000.
51.
ChenJJ, LyAV. Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm, 63:915–928. 2006.
52.
ChernyRA, AtwoodCS, XilinasME, GrayDN, JonesWD, McLeanCA, BarnhamKJ, VolitakisI, FraserFW, KimY, HuangX, GoldsteinLE, MoirRD, LimJT, BeyreutherK, ZhengH, TanziRE, MastersCL, BushAI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 30:665–676. 2001.
ChoiYT, JungCH, LeeSR, BaeJH, BaekWK, SuhMH, ParkJ, ParkCW, SuhSI. The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci, 70:603–614. 2001.
55.
ChuK, JungKH, KimSJ, LeeST, KimJ, ParkHK, SongEC, KimSU, KimM, LeeSK, RohJK. Transplantation of human neural stem cells protect against ischemia in a preventive mode via hypoxia-inducible factor-1alpha stabilization in the host brain. Brain Res, 1207:182–192. 2008.
56.
CohenG. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann N Y Acad Sci, 899:112–120. 2000.
ConnorJR, MenziesSL. Cellular management of iron in the brain. J Neurol Sci, 134,suppl:33–44. 1995.
59.
ConnorJR, MenziesSL, St MartinSM, MufsonEJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res, 31:75–83. 1992.
60.
CozzolinoM, FerriA, CarriMT. Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid Redox Signal, 10:405–443. 2008.
61.
Crapper McLachlanDR, DaltonAJ, KruckTP, BellMY, SmithWL, KalowW, AndrewsDF. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet, 337:1304–1328. 1991.
62.
CrichtonRR, PierreJL. Old iron, young copper: from Mars to Venus. Biometals, 14:99–112. 2001.
63.
CroninS, BergerS, DingJ, SchymickJC, WasheckaN, HernandezDG, GreenwayMJ, BradleyDG, TraynorBJ, HardimanO. A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet, 17:768–774. 2008.
64.
CrowJP, CalingasanNY, ChenJ, HillJL, BealMF. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol, 58:258–265. 2005.
DedeogluA, CormierK, PaytonS, TseitlinKA, KremskyJN, LaiL, LiX, MoirRD, TanziRE, BushAI, KowallNW, RogersJT, HuangX. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol, 39:1641–1649. 2004.
70.
Del BoR, GhezziS, ScarpiniE, BresolinN, ComiGP. VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. J Neurol Sci, 283:66–68. 2009.
71.
DemougeotC, Van HoeckeM, BertrandN, Prigent-TessierA, MossiatC, BeleyA, MarieC. Cytoprotective efficacy and mechanisms of the liposoluble iron chelator 2,2'-dipyridyl in the rat photothrombotic ischemic stroke model. J Pharmacol Exp Ther, 311:1080–1087. 2004.
EbadiM, SharmaS, ShavaliS, El RefaeyH. Neuroprotective actions of selegiline. J Neurosci Res, 67:285–289. 2002.
74.
EhrnhoeferDE, DuennwaldM, MarkovicP, WackerJL, EngemannS, RoarkM, LegleiterJ, MarshJL, ThompsonLM, LindquistS, MuchowskiPJ, WankerEE. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet, 15:2743–2751. 2006.
75.
EpsteinAC, GleadleJM, McNeillLA, HewitsonKS, O'RourkeJ, MoleDR, MukherjiM, MetzenE, WilsonMI, DhandaA, TianYM, MassonN, HamiltonDL, JaakkolaP, BarsteadR, HodgkinJ, MaxwellPH, PughCW, SchofieldCJ, RatcliffePJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107:43–54. 2001.
76.
FaheyJW, KenslerTW. Role of dietary supplements/nutraceuticals in chemoprevention through induction of cytoprotective enzymes. Chem Res Toxicol, 20:572–576. 2007.
77.
FandreyJ. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol, 286:R977–R988. 2004.
78.
FaucheuxBA, BonnetAM, AgidY, HirschEC. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet, 353:981–982. 1999.
FlugelD, GorlachA, MichielsC, KietzmannT. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol, 27:3253–3265. 2007.
81.
FowlerCJ, WibergA, OrelandL, MarcussonJ, WinbladB. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transmission, 49:1–20. 1980.
82.
FowlerJS, LoganJ, WangGJ, VolkowND, ZhuW, FranceschiD, PappasN, FerrieriR, SheaC, GarzaV, XuY, MacGregorRR, SchlyerD, GatleySJ, DingYS, AlexoffD. PET imaging of monoamine oxidase B in peripheral organs in humans. J Nucl Med, 43:1331–1338. 2002.
83.
FraislP, AragonesJ, CarmelietP. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov, 8:139–152. 2009.
84.
FredeS, StockmannC, FreitagP, FandreyJ. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB. Biochem J, 396:517–527. 2006.
85.
FreretT, ValableS, ChazalvielL, SaulnierR, MackenzieET, PetitE, BernaudinM, BoulouardM, Schumann-BardP. Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. Eur J Neurosci, 23:1757–1765. 2006.
86.
FridovichI. Superoxide dismutases. Annu Rev Biochem, 44:147–159. 1975.
87.
FukuiH, MoraesCT. The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis?Trends Neurosci, 31:251–256. 2008.
88.
GalS, FridkinM, AmitT, ZhengH, YoudimMB. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J Neural TransmSuppl:447–456. 2006.
89.
GalS, ZhengH, FridkinM, YoudimMB. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem, 95:79–88. 2005.
90.
GalS, ZhengH, FridkinM, YoudimMB. Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res, 2009, DOI:10.1007/s12640-009-9070-9079.
91.
GassenM, YoudimMB. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol Toxicol, 80:159–166. 1997.
92.
GencS, KorogluTF, GencK. Erythropoietin and the nervous system. Brain Res, 1000:19–31. 2004.
93.
GencS, KorogluTF, GencK. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci, 22:105–119. 2004.
94.
GerlachM, DoubleKL, YoudimMB, RiedererP. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transmissionsuppl:133–142. 2006.
95.
GerlachM, DoubleKL, YoudimMBH, RiedererP. Strategies for the protection of dopaminergic neurons against neurotoxicity. Neurotoxicol Ressuppl 2:99–114. 2000.
96.
GiddayJM, FitzgibbonsJC, ShahAR, ParkTS. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat. Neurosci Lett, 168:221–224. 1994.
97.
GorresKL, PuaKH, RainesRT. Stringency of the 2-His-1-Asp active-site motif in prolyl 4-hydroxylase. PLoS One, 4:e7635. 2009.
98.
GotzME, DoubleK, GerlachM, YoudimMB, RiedererP. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci, 1012:193–208. 2004.
99.
GotzME, KunigG, RiedererP, YoudimMB. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther, 63:37–122. 1994.
100.
GrunblattE, MandelS, Jacob-HirschJ, ZeligsonS, AmarigloN, RechaviG, LiJ, RavidR, RoggendorfW, RiedererP, YoudimMB. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm, 111:1543–1573. 2004.
101.
Grundke-IqbalI, FlemingJ, TungYC, LassmannH, IqbalK, JoshiJG. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol, 81:105–110. 1990.
102.
GuoQ, ZhaoB, LiM, ShenS, XinW. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys Acta, 1304:210–222. 1996.
103.
GuoS, BraginaO, XuY, CaoZ, ChenH, ZhouB, MorganM, LinY, JiangBH, LiuKJ, ShiH. Glucose up-regulates HIF-1 alpha expression in primary cortical neurons in response to hypoxia through maintaining cellular redox status. J Neurochem, 105:1849–1860. 2008.
104.
HalliwellB. Reactive oxygen species and the central nervous system. J Neurochem, 59:1609–1623. 1992.
105.
HalliwellB. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging, 18:685–716. 2001.
106.
HalliwellB. Oxidative stress and neurodegeneration: where are we now?J Neurochem, 97:1634–1658. 2006.
107.
HalliwellB. Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies?Arch Biochem Biophys, 476:107–112. 2008.
108.
HamrickSE, McQuillenPS, JiangX, MuD, MadanA, FerrieroDM. A role for hypoxia-inducible factor-1alpha in desferoxamine neuroprotection. Neurosci Lett, 379:96–100. 2005.
109.
HanJ, ChengFC, YangZ, DryhurstG. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. J Neurochem, 73:1683–1695. 1999.
110.
Hanauske-AbelHM. Prolyl 4-hydroxylase, a target enzyme for drug development: design of suppressive agents and the in vitro effects of inhibitors and proinhibitors. J Hepatol, 13,suppl 3:S8–S15discussion S161991.
111.
HansonES, RawlinsML, LeiboldEA. Oxygen and iron regulation of iron regulatory protein 2. J Biol Chem, 278:40337–40342. 2003.
112.
HartenSK, AshcroftM, MaxwellPH. Prolyl hydroxylase domain inhibitors: a route to HIF activation and neuroprotection. Antioxid Redox Signal, 12:459–480. 2010.
113.
HegdeML, BharathiP, SuramA, VenugopalC, JagannathanR, PoddarP, SrinivasP, SambamurtiK, RaoKJ, ScancarJ, MessoriL, ZeccaL, ZattaP. Challenges associated with metal chelation therapy in Alzheimer's disease. J Alzheimers Dis, 17:457–468. 2009.
HewitsonKS, McNeillLA, SchofieldCJ. Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr Pharm Des, 10:821–33. 2004.
116.
HewitsonKS, SchofieldCJ. The HIF pathway as a therapeutic target. Drug Disc Today, 9:704–711. 2004.
117.
HidalgoC, CarrascoMA, MunozP, NunezMT. A role for reactive oxygen/nitrogen species and iron on neuronal synaptic plasticity. Antioxid Redox Signal, 9:245–255. 2007.
118.
HiderRC, MaY, Molina-HolgadoF, GaetaA, RoyS. Iron chelation as a potential therapy for neurodegenerative disease. Biochem Soc Trans, 36:1304–1308. 2008.
119.
HigdonJV, FreiB. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr, 43:89–143. 2003.
120.
HirschEC. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. Mol Neurobiol, 9:135–142. 1994.
121.
HirsilaM, KoivunenP, XuL, SeeleyT, KivirikkoKI, MyllyharjuJ. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J, 19:1308–1310. 2005.
HouseE, CollingwoodJ, KhanA, KorchazkinaO, BerthonG, ExleyC. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimers Dis, 6:291–301. 2004.
124.
HurE, ChangKY, LeeE, LeeSK, ParkH. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. Mol Pharmacol, 59:1216–1224. 2001.
125.
IbrahimNO, HahnT, FrankeC, StiehlDP, WirthnerR, WengerRH, KatschinskiDM. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors. Cancer Res, 65:11094–11100. 2005.
126.
IliopoulosO, LevyAP, JiangC, KaelinWGJr, GoldbergMA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A, 93:10595–10599. 1996.
127.
ImonY, YamaguchiS, YamamuraY, TsujiS, KajimaT, ItoK, NakamuraS. Low intensity areas observed on T2-weighted magnetic resonance imaging of the cerebral cortex in various neurological diseases. J Neurol Sci, 134,suppl:27–32. 1995.
128.
IshigeK, SchubertD, SagaraY. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med, 30:433–446. 2001.
129.
JaakkolaP, MoleDR, TianYM, WilsonMI, GielbertJ, GaskellSJ, KriegsheimA, HebestreitHF, MukherjiM, SchofieldCJ, MaxwellPH, PughCW, RatcliffePJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 292:468–472. 2001.
130.
JellingerK, LinertL, KienzlE, HerlingerE, YoudimMBH. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transmission Suppl, 46:297–314. 1995.
131.
JellingerKA. Post mortem studies in Parkinson's disease: is it possible to detect brain areas for specific symptoms?J Neural TransmissionSuppl:1–29. 1991.
132.
JellingerKA. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging, 14:115–140. 1999.
133.
JennerP. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand Suppl, 136:6–15. 1991.
134.
JennerP. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord, 13:24–34. 1998.
135.
JennerP, OlanowCW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology, 47:S161–S170. 1996.
136.
JennerP, OlanowCW. Understanding cell death in Parkinson's disease. Ann Neurol, 44:S72–S84. 1998.
137.
JeonH, KimH, ChoiD, KimD, ParkSY, KimYJ, KimYM, JungY. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol Pharmacol, 71:1676–1684. 2007.
138.
JeongJW, BaeMK, AhnMY, KimSH, SohnTK, BaeMH, YooMA, SongEJ, LeeKJ, KimKW. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell, 111:709–720. 2002.
139.
JeongSY, RathoreKI, SchulzK, PonkaP, ArosioP, DavidS. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci, 29:610–619. 2009.
JohnDC, BulleidNJ. Intracellular dissociation and reassembly of prolyl 4-hydroxylase: the alpha-subunits associated with the immunoglobulin-heavy-chain binding protein (BiP) allowing reassembly with the beta-subunit. Biochem J, 317:659–665. 1996.
142.
JonesNM, KardashyanL, CallawayJK, LeeEM, BeartPM. Long-term functional and protective actions of preconditioning with hypoxia, cobalt chloride, and desferrioxamine against hypoxic-ischemic injury in neonatal rats. Pediatr Res, 63:620–624. 2008.
143.
JosephJA, Shukitt-HaleB, CasadesusG. Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. Am J Clin Nutr, 81:313S–316S. 2005.
144.
JosephJA, Shukitt-HaleB, CasadesusG, FisherD. Oxidative stress and inflammation in brain aging: nutritional considerations. Neurochem Res, 30:927–935. 2005.
145.
KaelinWG. Proline hydroxylation and gene expression. Annu Rev Biochem, 74:115–128. 2005.
146.
KalfonL, YoudimMB, MandelSA. Green tea polyphenol (-)-epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of Bad: implications for neuroprotection. J Neurochem, 100:992–1002. 2007.
147.
KasarskisEJ, TandonL, LovellMA, EhmannWD. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J Neurol Sci, 130:203–208. 1995.
148.
KatoH, AmersiF, BuelowR, MelinekJ, CoitoAJ, KeB, BusuttilRW, Kupiec-WeglinskiJW. Heme oxygenase-1 overexpression protects rat livers from ischemia/reperfusion injury with extended cold preservation. Am J Transplant, 1:121–128. 2001.
149.
KatschinskiDM, LeL, SchindlerSG, ThomasT, VossAK, WengerRH. Interaction of the PAS B domain with HSP90 accelerates hypoxia-inducible factor-1alpha stabilization. Cell Physiol Biochem, 14:351–360. 2004.
150.
KaurD, YantiriF, RajagopalanS, KumarJ, MoJQ, BoonplueangR, ViswanathV, JacobsR, YangL, BealMF, DiMonteD, VolitaskisI, EllerbyL, ChernyRA, BushAI, AndersenJK. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron, 37:899–909. 2003.
151.
KeberleH. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci, 119:758–768. 1964.
152.
KimJW, TchernyshyovI, SemenzaGL, DangCV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab, 3:177–185. 2006.
153.
KitaniK, KanaiS, IvyGO, CarrilloMC. Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy. Mech Ageing Dev, 111:211–221. 1999.
154.
KobayashiS, HarrisVA, WelshFA. Spreading depression induces tolerance of cortical neurons to ischemia in rat brain. J Cereb Blood Flow Metab, 15:721–727. 1995.
KohSH, LeeSM, KimHY, LeeKY, LeeYJ, KimHT, KimJ, KimMH, HwangMS, SongC, YangKW, LeeKW, KimSH, KimOH. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci Lett, 395:103–107. 2006.
157.
KrizJ, NguyenMD, JulienJP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis, 10:268–278. 2002.
158.
KumamotoM, SondaT, NagayamaK, TabataM. Effects of pH and metal ions on antioxidative activities of catechins. Biosci Biotechnol Biochem, 65:126–132. 2001.
159.
KupershmidtL, WeinrebO, AmitT, MandelS, CarriMT, YoudimMB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J, 23:3766–3779. 2009.
160.
LaiCT, ZuoDM, YuPH. Is brain superoxide dismutase activity increased following chronic treatment with 1-deprenyl?J Neural Transmission Suppl, 41:221–229. 1994.
161.
LambrechtsD, StorkebaumE, MorimotoM, Del-FaveroJ, DesmetF, MarklundSL, WynsS, ThijsV, AnderssonJ, van MarionI, Al-ChalabiA, BornesS, MussonR, HansenV, BeckmanL, AdolfssonR, PallHS, PratsH, VermeireS, RutgeertsP, KatayamaS, AwataT, LeighN, Lang-LazdunskiL, DewerchinM, ShawC, MoonsL, VlietinckR, MorrisonKE, RobberechtW, Van BroeckhovenC, CollenD, AndersenPM, CarmelietP. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet, 34:383–394. 2003.
162.
LanJ, JiangDH. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transmission (Budapest), 104:469–481. 1997.
163.
LanJ, JiangDH. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J Neural Transmission, 104:649–660. 1997.
164.
LannfeltL, BlennowK, ZetterbergH, BatsmanS, AmesD, HarrisonJ, MastersCL, TargumS, BushAI, MurdochR, WilsonJ, RitchieCW. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol, 7:779–786. 2008.
165.
LaVauteT, SmithS, CoopermanS, IwaiK, LandW, Meyron-HoltzE, DrakeSK, MillerG, Abu-AsabM, TsokosM, SwitzerR3rd, GrinbergA, LoveP, TresserN, RouaultTA. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nature Genet, 27:209–214. 2001.
166.
LazaroviciP, GazitA, StaniszewskaI, MarcinkiewiczC, LelkesPI. Nerve growth factor (NGF) promotes angiogenesis in the quail chorioallantoic membrane. Endothelium, 13:51–59. 2006.
167.
LeeDW, AndersenJK. Role of HIF-1 in iron regulation: potential therapeutic strategy for neurodegenerative disorders. Curr Mol Med, 6:883–893. 2006.
168.
LeeDW, RajagopalanS, SiddiqA, GwiazdaR, YangL, BealMF, RatanRR, AndersenJK. Inhibition of prolyl hydroxylase protects against MPTP-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson's disease. J Biol Chem, 284:29065–29076. 2009.
169.
LeeKA, RothRA, LaPresJJ. Hypoxia, drug therapy and toxicity. Pharmacol Ther, 113:229–246. 2007.
170.
LeeKH, ChoiE, ChunYS, KimMS, ParkJW. Differential responses of two degradation domains of HIF-1alpha to hypoxia and iron deficiency. Biochimie, 88:163–169. 2006.
171.
LeePJ, JiangBH, ChinBY, IyerNV, AlamJ, SemenzaGL, ChoiAM. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem, 272:5375–5381. 1997.
172.
LeeS, NakamuraE, YangH, WeiW, LinggiMS, SajanMP, FareseRV, FreemanRS, CarterBD, KaelinWGJr, SchlisioS. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell, 8:155–167. 2005.
173.
LeeS, SuhS, KimS. Protective effects of the green tea polyphenol (-)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci Lett, 287:191–194. 2000.
LesageS, BriceA. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet, 18:R48–R59. 2009.
176.
LevitesY, AmitT, MandelS, YoudimMBH. Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J, 17:952–954. 2003.
177.
LevitesY, AmitT, YoudimMB, MandelS. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem, 277:30574–30580. 2002.
LiR, PengN, DuF, LiXP, LeWD. Epigallocatechin gallate protects dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by inhibiting microglial cell activation. Nan Fang Yi Ke Da Xue Xue Bao, 26:376–380. 2006.
180.
LiYX, DingSJ, XiaoL, GuoW, ZhanQ. Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci Bull, 24:89–95. 2008.
181.
LiZ, YaK, Xiao-MeiW, LeiY, YangL, MingQZ. Ginkgolides protect PC12 cells against hypoxia-induced injury by p42/p44 MAPK pathway-dependent upregulation of HIF-1alpha expression and HIF-1DNA-binding activity. J Cell Biochem, 103:564–575. 2008.
182.
LinertW, HerlingerE, JamesonRF, KienzlE, JellingerK, YoudimMBH. Dopamine, 6-hydroxydopamine, iron, and dioxygen: their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta, 1316:160–168. 1996.
183.
LiuJ, GinisI, SpatzM, HallenbeckJM. Hypoxic preconditioning protects cultured neurons against hypoxic stress via TNF-alpha and ceramide. Am J Physiol Cell Physiol, 278:C144–C153. 2000.
184.
LiuY, LiuF, IqbalK, Grundke-IqbalI, GongCX. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett, 582:359–364. 2008.
185.
LongLH, ClementMV, HalliwellB. Artifacts in cell culture: rapid generation of hydrogen peroxide on addition of (-)-epigallocatechin, (-)-epigallocatechin gallate, (+)-catechin, and quercetin to commonly used cell culture media. Biochem Biophys Res Commun, 273:50–53. 2000.
MaherP, AkaishiT, AbeK. Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc Natl Acad Sci U S A, 103:16568–16573. 2006.
192.
MajamaaK, GunzlerV, Hanauske-AbelHM, MyllylaR, KivirikkoKI. Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. J Biol Chem, 261:7819–7823. 1986.
193.
MandelSA, Avramovich-TiroshY, ReznichenkoL, ZhengH, WeinrebO, AmitT, YoudimMB. Multifunctional activities of green tea catechins in neuroprotection: modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals, 14:46–60. 2005.
194.
MaruyamaW, AkaoY, CarrilloMC, KitaniK, YoudiumMB, NaoiM. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol, 24:675–682. 2002.
195.
MassonN, WillamC, MaxwellPH, PughCW, RatcliffePJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J, 20:5197–5206. 2001.
196.
MastrogiannakiM, MatakP, KeithB, SimonMC, VaulontS, PeyssonnauxC. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest, 119:1159–1166. 2009.
197.
MaxwellP, SalnikowK. HIF-1: an oxygen and metal responsive transcription factor. Cancer Biol Ther, 3:29–35. 2004.
198.
MaxwellPH. Hypoxia-inducible factor as a physiological regulator. Exp Physiol, 90:791–797. 2005.
199.
MaxwellPH, WiesenerMS, ChangGW, CliffordSC, VauxEC, CockmanME, WykoffCC, PughCW, MaherER, RatcliffePJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399:271–275. 1999.
200.
McDonoughMA, LiV, FlashmanE, ChowdhuryR, MohrC, LienardBM, ZondloJ, OldhamNJ, CliftonIJ, LewisJ, McNeillLA, KurzejaRJ, HewitsonKS, YangE, JordanS, SyedRS, SchofieldCJ. Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2)Proc Natl Acad Sci U S A, 103:9814–9819. 2006.
201.
McNaughtKS, JennerP. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett, 297:191–194. 2001.
202.
MendelGA. Studies on iron absorption, I: the relationships between the rate of erythropoiesis, hypoxia and iron absorption. Blood, 18:727–736. 1961.
203.
MikhaylovaO, IgnacakML, BarankiewiczTJ, HarbaughSV, YiY, MaxwellPH, SchneiderM, Van GeyteK, CarmelietP, ReveloMP, WyderM, GreisKD, MellerJ, Czyzyk-KrzeskaMF. The von Hippel-Lindau tumor suppressor protein and Egl-9-type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol Cell Biol, 28:2701–2717. 2008.
MishraRR, AdhikaryG, SimonsonMS, CherniackNS, PrabhakarNR. Role of c-fos in hypoxia-induced AP-1 cis-element activity and tyrosine hydroxylase gene expression. Brain Res Mol Brain Res, 59:74–83. 1998.
206.
MisseroC, CalauttiE, EcknerR, ChinJ, TsaiLH, LivingstonDM, DottoGP. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci U S A, 92:5451–5455. 1995.
207.
MizunoY, AmariM, TakatamaM, AizawaH, MiharaB, OkamotoK. Transferrin localizes in Bunina bodies in amyotrophic lateral sclerosis. Acta Neuropathol, 112:597–603. 2006.
MoosT, Rosengren NielsenT, SkjorringeT, MorganEH. Iron trafficking inside the brain. J Neurochem, 103:1730–1740. 2007.
210.
MoreiraPI, HondaK, LiuQ, SantosMS, OliveiraCR, AlievG, NunomuraA, ZhuX, SmithMA, PerryG. Oxidative stress: the old enemy in Alzheimer's disease pathophysiology. Curr Alzheimer Res, 2:403–408. 2005.
211.
MorseLJ, PaytonSM, CunyGD, RogersJT. FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J Mol Neurosci, 24:129–136. 2004.
212.
MuD, ChangYS, VexlerZS, FerrieroDM. Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp Neurol, 195:407–415. 2005.
213.
NangakuM, IzuharaY, TakizawaS, YamashitaT, Fujii-KuriyamaY, OhnedaO, YamamotoM, van Ypersele de StrihouC, HirayamaN, MiyataT. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol, 27:2548–2554. 2007.
214.
NapolitanoM, CentonzeD, CalceA, PicconiB, SpieziaS, GulinoA, BernardiG, CalabresiP. Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum. Neurobiol Dis, 10:387–395. 2002.
215.
NguyenMV, PouvreauS, El HajjajiFZ, Denavit-SaubieM, PequignotJM. Desferrioxamine enhances hypoxic ventilatory response and induces tyrosine hydroxylase gene expression in the rat brainstem in vivo. J Neurosci Res, 85:1119–1125. 2007.
216.
NieG, JinC, CaoY, ShenS, ZhaoB. Distinct effects of tea catechins on 6-hydroxydopamine-induced apoptosis in PC12 cells. Arch Biochem Biophys, 397:84–90. 2002.
217.
NorrisML, MillhornDE. Hypoxia-induced protein binding to O2-responsive sequences on the tyrosine hydroxylase gene. J Biol Chem, 270:23774–23779. 1995.
218.
NygrenI, LarssonA, JohanssonA, AskmarkH. VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis. Neuroreport, 13:2199–2201. 2002.
219.
ObaH, ArakiT, OhtomoK, MonzawaS, UchiyamaG, KoizumiK, NogataY, KachiK, ShiozawaZ, KobayashiM. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology, 189:843–846. 1993.
220.
ObregonDF, Rezai-ZadehK, BaiY, SunN, HouH, EhrhartJ, ZengJ, MoriT, ArendashGW, ShytleD, TownT, TanJ. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem, 281:16419–16427. 2006.
221.
OgunsholaOO, AntoniouX. Contribution of hypoxia to Alzheimer's disease: is HIF-1alpha a mediator of neurodegeneration?Cell Mol Life Sci, 66:3555–3563. 2009.
222.
OlanowCW. Oxidation reactions in Parkinson's disease. Neurology, 40,suppl:32–37discussion 37–391990.
223.
OlanowCW. Early therapy for Parkinson's disease. Eur Neurol, 32:30–35. 1992.
224.
OlanowCW, HauserRA, JankovicJ, LangstonW, LangA, PoeweW, TolosaE, StocchiF, MelamedE, EyalE, RascolO. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord, 23:2194–2201. 2008.
225.
OlanowCW, RascolO, HauserR, FeiginPD, JankovicJ, LangA, LangstonW, MelamedE, PoeweW, StocchiF, TolosaE. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med, 361:1268–1278. 2009.
226.
OlanowCW, SternMB, SethiK. The scientific and clinical basis for the treatment of Parkinson disease. Neurology, 72:S1–S136. 2009.
227.
PalmerC, MenziesSL, RobertsRL, PavlickG, ConnorJR. Changes in iron histochemistry after hypoxic-ischemic brain injury in the neonatal rat. J Neurosci Res, 56:60–71. 1999.
ParkSS, BaeI, LeeYJ. Flavonoids-induced accumulation of hypoxia-inducible factor (HIF)-1alpha/2alpha is mediated through chelation of iron. J Cell Biochem, 103:1989–1998. 2008.
230.
Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med., 321:176–183. 1989.
231.
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease. Arch Neurol, 59:1937–1993. 2002.
232.
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol, 61:561–566. 2004.
233.
PaytonS, CahillCM, RandallJD, GullansSR, RogersJT. Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol. J Mol Neurosci, 20:267–275. 2003.
234.
PengZ, RenP, KangZ, DuJ, LianQ, LiuY, ZhangJH, SunX. Up-regulated HIF-1alpha is involved in the hypoxic tolerance induced by hyperbaric oxygen preconditioning. Brain Res, 1212:71–78. 2008.
235.
PerronNR, BrumaghimJL. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys, 53:75–100. 2009.
236.
PerronNR, HodgesJN, JenkinsM, BrumaghimJL. Predicting how polyphenol antioxidants prevent DNA damage by binding to iron. Inorg Chem, 47:6153–6161. 2008.
237.
PerryTL, GodinDV, HansenS. Parkinson's disease: a disorder due to nigral glutathione deficiency?Neurosci Lett, 33:305–310. 1982.
238.
PeyssonnauxC, ZinkernagelAS, SchuepbachRA, RankinE, VaulontS, HaaseVH, NizetV, JohnsonRS. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)J Clin Invest, 117:1926–1932. 2007.
239.
PineroDJ, HuJ, ConnorJR. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. Cell Mol Biol (Noisy-Le-Grand), 46:761–776. 2000.
240.
PiretJP, LecocqC, ToffoliS, NinaneN, RaesM, MichielsC. Hypoxia and CoCl2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. Exp Cell Res, 295:340–349. 2004.
241.
PrassK, RuscherK, KarschM, IsaevN, MegowD, PrillerJ, ScharffA, DirnaglU, MeiselA. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cereb Blood Flow Metab, 22:520–525. 2002.
242.
PraticoD, DelantyN. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med, 109:577–585. 2000.
243.
PrzedborskiS. Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance. Neurologist, 10:1–7. 2004.
244.
RabieT, MartiHH. Brain protection by erythropoietin: a manifold task. Physiology (Bethesda), 23:263–274. 2008.
245.
RanR, XuH, LuA, BernaudinM, SharpFR. Hypoxia preconditioning in the brain. Dev Neurosci, 27:87–92. 2005.
246.
RatanRR, SiddiqA, AminovaL, LangleyB, McConougheyS, KarpishevaK, LeeHH, CarmichaelT, KornblumH, CoppolaG, GeschwindDH, HokeA, SmirnovaN, RinkC, RoyS, SenC, BeattieMS, HartRP, GrumetM, SunD, FreemanRS, SemenzaGL, GazaryanI. Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury. Ann N Y Acad Sci, 1147:383–394. 2008.
247.
Rezai-ZadehK, ArendashGW, HouH, FernandezF, JensenM, RunfeldtM, ShytleRD, TanJ. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res, 1214:177–187. 2008.
248.
Rezai-ZadehK, ShytleD, SunN, MoriT, HouH, JeannitonD, EhrhartJ, TownsendK, ZengJ, MorganD, HardyJ, TownT, TanJ. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci, 25:8807–8814. 2005.
249.
ReznichenkoL, AmitT, YoudimMB, MandelS. Green tea polyphenol (-)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth. J Neurochem, 93:1157–1167. 2005.
250.
ReznichenkoL, AmitT, ZhengH, Avramovich-TiroshY, YoudimMB, WeinrebO, MandelS. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem, 97:527–536. 2006.
251.
Rice-EvansC. Flavonoid antioxidants. Curr Med Chem, 8:797–807. 2001.
252.
RichardsonDR. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann N Y Acad Sci, 1012:326–341. 2004.
253.
RiedererP, DirrA, GoetzM, SoficE, JellingerK, YoudimMBH. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol, 32,suppl:S101–S104. 1992.
RitchieCW, BushAI, MackinnonA, MacfarlaneS, MastwykM, MacGregorL, KiersL, ChernyR, LiQX, TammerA, CarringtonD, MavrosC, VolitakisI, XilinasM, AmesD, DavisS, BeyreutherK, TanziRE, MastersCL. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol, 60:1685–1691. 2003.
256.
RogersJ, CooperNR, WebsterS, SchultzJ, McGeerPL, StyrenSD, CivinWH, BrachovaL, BradtB, WardP. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A, 89:10016–10020. 1992.
257.
RogersJT, BushAI, ChoHH, SmithDH, ThomsonAM, FriedlichAL, LahiriDK, LeedmanPJ, HuangX, CahillCM. Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. Biochem Soc Trans, 36:1282–1287. 2008.
258.
RogersJT, LahiriDK. Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets, 5:535–551. 2004.
259.
RogersJT, RandallJD, CahillCM, EderPS, HuangX, GunshinH, LeiterL, McPheeJ, SarangSS, UtsukiT, GreigNH, LahiriDK, TanziRE, BushAI, GiordanoT, GullansSR. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem, 277:45518–45528. 2002.
RouaultTA, CoopermanS. Brain iron metabolism. Semin Pediatr Neurol, 13:142–148. 2006.
266.
RoyA, VolginDV, BabySM, MokashiA, KubinL, LahiriS. Activation of HIF-1alpha mRNA by hypoxia and iron chelator in isolated rat carotid body. Neurosci Lett, 363:229–232. 2004.
267.
SabbaghA, YoudimMBH. Selective inhibition of monoamine oxidase type B by propargyl-containing drugs. Israel J Med Sci, 14:1097. 1978.
268.
SagiY, MandelS, AmitT, YoudimMB. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis, 25:35–44. 2007.
269.
SalnikowK, SuW, BlagosklonnyMV, CostaM. Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen species-independent mechanism. Cancer Res, 60:3375–3378. 2000.
270.
SalvatoreMF, FisherB, SurgenerSP, GerhardtGA, RouaultT. Neurochemical investigations of dopamine neuronal systems in iron-regulatory protein 2 (IRP-2) knockout mice. Brain Res Mol Brain Res, 139:341–347. 2005.
271.
SarcoDP, BeckerJ, PalmerC, SheldonRA, FerrieroDM. The neuroprotective effect of deferoxamine in the hypoxic-ischemic immature mouse brain. Neurosci Lett, 282:113–116. 2000.
272.
SauraJ, LuqueJM, CesuraAM, Da PradaM, Chan-PalayV, HuberG, LofflerJ, RichardsJG. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience, 62:15–30. 1994.
273.
SayreLM, PerryG, HarrisPL, LiuY, SchubertKA, SmithMA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem, 74:270–279. 2000.
274.
SayreLM, SmithMA, PerryG. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem, 8:721–738. 2001.
275.
SchapiraAH, OlanowCW. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol, 64,suppl 2:S47–S55. 2008.
276.
SchipperHM. Heme oxygenase expression in human central nervous system disorders. Free Radic Biol Med, 37:1995–2011. 2004.
277.
SchliebsR. Basal forebrain cholinergic dysfunction in Alzheimer's disease: interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res, 30:895–908. 2005.
278.
SchnellPO, IgnacakML, BauerAL, StrietJB, PauldingWR, Czyzyk-KrzeskaMF. Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors. J Neurochem, 85:483–491. 2003.
SemenzaGL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3:721–732. 2003.
284.
SemenzaGL, RothPH, FangHM, WangGL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem, 269:23757–23763. 1994.
285.
SemenzaGL, WangGL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol, 12:5447–5454. 1992.
286.
SenCK, PackerL. Antioxidant and redox regulation of gene transcription. FASEB J, 10:709–720. 1996.
287.
SharpFR, BergeronM, BernaudinM. Hypoxia-inducible factor in brain. Adv Exp Med Biol, 502:273–591. 2001.
288.
ShimohamaS, TaninoH, KawakamiN, OkamuraN, KodamaH, YamaguchiT, HayakawaT, NunomuraA, ChibaS, PerryG, SmithMA, FujimotoS. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun, 273:5–9. 2000.
289.
ShoulsonI. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease: the Parkinson Study Group. Eur Neurol, 32,suppl 1:46–53. 1992.
290.
SiddiqA, AminovaLR, RatanRR. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem Res, 32:931–946. 2007.
291.
SiddiqA, AminovaLR, RatanRR. Prolyl 4-hydroxylase activity-responsive transcription factors: from hydroxylation to gene expression and neuroprotection. Front Biosci, 13:2875–2887. 2008.
292.
SiddiqA, AminovaLR, TroyCM, SuhK, MesserZ, SemenzaGL, RatanRR. Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways. J Neurosci, 29:8828–8838. 2009.
293.
SiddiqA, AyoubIA, ChavezJC, AminovaL, ShahS, LaMannaJC, PattonSM, ConnorJR, ChernyRA, VolitakisI, BushAI, LangsetmoI, SeeleyT, GunzlerV, RatanRR. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition: a target for neuroprotection in the central nervous system. J Biol Chem, 280:41732–41743. 2005.
294.
SinghVP, SalujaAK, BhagatL, van AckerGJ, SongAM, SoltoffSP, CantleyLC, SteerML. Phosphatidylinositol 3-kinase-dependent activation of trypsinogen modulates the severity of acute pancreatitis. J Clin Invest, 108:1387–1395. 2001.
295.
SivakumarV, LuJ, LingEA, KaurC. Vascular endothelial growth factor and nitric oxide production in response to hypoxia in the choroid plexus in neonatal brain. Brain Pathol, 18:71–85. 2008.
296.
SmithDG, CappaiR, BarnhamKJ. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta, 1768:1976–1990. 2007.
297.
SmithMA, HarrisPL, SayreLM, PerryG. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A, 94:9866–9868. 1997.
298.
SmithMA, HiraiK, HsiaoK, PappollaMA, HarrisPL, SiedlakSL, TabatonM, PerryG. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem, 70:2212–2215. 1998.
SmithMA, WehrK, HarrisPL, SiedlakSL, ConnorJR, PerryG. Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res, 788:232–326. 1998.
301.
SmithSR, CoopermanS, LavauteT, TresserN, GhoshM, Meyron-HoltzE, LandW, OllivierreH, JortnerB, SwitzerR3rd, MessingA, RouaultTA. Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies. Ann N Y Acad Sci, 1012:65–83. 2004.
302.
SnowdonDA. Healthy aging and dementia: findings from the Nun Study. Ann Intern Med, 139:450–454. 2003.
303.
SoucekT, CummingR, DarguschR, MaherP, SchubertD. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron, 39:43–56. 2003.
304.
SterlingJ, VeinbergA, LernerD, GoldenbergW, LevyR, YoudimM, FinbergJ. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transmission Suppl, 52:301–305. 1998.
305.
StockmannC, FandreyJ. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin Exp Pharmacol Physiol, 33:968–979. 2006.
306.
StreiflerM, RabeyMJ. Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients. J Neural Transmission Suppl, 19:265–272. 1983.
SutedjaNA, SinkeRJ, Van VughtPW, Van der LindenMW, WokkeJH, Van DuijnCM, NjajouOT, Van der SchouwYT, VeldinkJH, Van den BergLH. The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Arch Neurol, 64:63–67. 2007.
309.
SutherlandBA, RahmanRM, AppletonI. Mechanisms of action of green tea catechins, with a focus on ischemia-induced neurodegeneration. J Nutr Biochem, 17:291–306. 2006.
310.
SutherlandBA, ShawOM, ClarksonAN, JacksonDN, SammutIA, AppletonI. Neuroprotective effects of (-)-epigallocatechin gallate following hypoxia-ischemia-induced brain damage: novel mechanisms of action. FASEB J, 19:258–260. 2005.
311.
TakedaA, PerryG, AbrahamNG, DwyerBE, KuttyRK, LaitinenJT, PetersenRB, SmithMA. Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J Biol Chem, 275:5395–5399. 2000.
312.
TattonWG, Chalmers-RedmanRM, JuWJ, MammenM, CarlileGW, PongAW, TattonNA. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther, 301:753–764. 2002.
313.
TaylorCT, PouyssegurJ. Oxygen, hypoxia, and stress. Ann N Y Acad Sci, 1113:87–94. 2007.
314.
ThomasR, KimMH. Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. Biochem Biophys Res Commun, 334:543–548. 2005.
315.
TianB, SunZ, XuZ, HuaY. Chemiluminescence analysis of the prooxidant and antioxidant effects of epigallocatechin-3-gallate. Asia Pac J Clin Nutr, 16,suppl 1:153–157. 2007.
316.
TreiberC, SimonsA, StraussM, HafnerM, CappaiR, BayerTA, MulthaupG. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem, 279:51958–51964. 2004.
317.
TriantafyllouA, LiakosP, TsakalofA, ChachamiG, ParaskevaE, MolyvdasPA, GeorgatsouE, SimosG, BonanouS. The flavonoid quercetin induces hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. Free Radic Res, 41:342–356. 2007.
318.
TriantafyllouA, MylonisI, SimosG, BonanouS, TsakalofA. Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity. Free Radic Biol Med, 44:657–670. 2008.
319.
TsolakiM, KokaridaK, IakovidouV, StilopoulosE, MeimarisJ, KazisA. Extrapyramidal symptoms and signs in Alzheimer's disease: prevalence and correlation with the first symptom. Am J Alzheimers Dis Other Dement, 16:268–278. 2001.
320.
TurnerBJ, TalbotK. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol, 85:94–134. 2008.
321.
UrushitaniM, EzziSA, JulienJP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A, 104:2495–2500. 2007.
322.
ValdmanisPN, DaoudH, DionPA, RouleauGA. Recent advances in the genetics of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep, 9:198–205. 2009.
323.
van AckerSA, van den BergDJ, TrompMN, GriffioenDH, van BennekomWP, van der VijghWJ, BastA. Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med, 20:331–342. 1996.
324.
VeijolaJ, PihlajaniemiT, KivirikkoKI. Co-expression of the alpha subunit of human prolyl 4-hydroxylase with BiP polypeptide in insect cells leads to the formation of soluble and insoluble complexes: soluble alpha-subunit-BiP complexes have no prolyl 4-hydroxylase activity. Biochem J, 315:613–618. 1996.
325.
VexlerZS, FerrieroDM. Molecular and biochemical mechanisms of perinatal brain injury. Semin Neonatol, 6:99–108. 2001.
326.
WaibelS, ReuterA, MalessaS, BlaugrundE, LudolphAC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol, 251:1080–1084. 2004.
327.
WangGL, SemenzaGL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem, 270:1230–1237. 1995.
328.
WangXS, LeeS, SimmonsZ, BoyerP, ScottK, LiuW, ConnorJ. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci, 227:27–33. 2004.
329.
WarneckeC, GrietheW, WeidemannA, JurgensenJS, WillamC, BachmannS, IvashchenkoY, WagnerI, FreiU, WiesenerM, EckardtKU. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J, 17:1186–1188. 2003.
330.
WarshakoonNC, WuS, BoyerA, KawamotoR, ShevilleJ, RenockS, XuK, PokrossM, ZhouS, WinterC, WalterR, MekelM, EvdokimovAG. Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1alpha prolyl hydroxylase inhibitors. Bioorg Med Chem Lett, 16:5517–5522. 2006.
331.
WeiIH, WuYC, WenCY, ShiehJY. Green tea polyphenol (-)-epigallocatechin gallate attenuates the neuronal NADPH-d/nNOS expression in the nodose ganglion of acute hypoxic rats. Brain Res, 999:73–80. 2004.
332.
WeinrebO, AmitT, YoudimMB. A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Radic Biol Med, 43:546–556. 2007.
333.
WeinrebO, AmitT, YoudimMB. The application of proteomics for studying the neurorescue activity of the polyphenol (-)-epigallocatechin-3-gallate. Arch Biochem Biophys, 476:152–160. 2008.
334.
WeinrebO, Bar-AmO, AmitT, Chillag-TalmorO, YoudimMBH. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J, 18:1471–1473. 2004.
335.
WeinrebO, Bar-AmO, AmitT, DriguesN, SagiY, YoudimMB. The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chem Biol Interact, 175:318–326. 2008.
336.
WeinrebO, MandelS, AmitT, YoudimMBH. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutri Biochem, 15:506–516. 2004.
337.
WeinrebO, MandelS, YoudimMBH. cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J, 17:935–937. 2003.
338.
WeinstockM, Kirschbaum-SlagerN, LazaroviciP, BejarC, ShoamiE, MBHY. Cell culture and in vivo neuroprotective effects of novel cholinesterase-MAO inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann N Y Acad Sci, 939:148–161. 2000.
339.
WhiteAR, DuT, LaughtonKM, VolitakisI, SharplesRA, XilinasME, HokeDE, HolsingerRM, EvinG, ChernyRA, HillAF, BarnhamKJ, LiQX, BushAI, MastersCL. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem, 281:17670–17680. 2006.
340.
WhitnallM, RichardsonDR. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol, 13:186–197. 2006.
341.
WiesenerMS, JurgensenJS, RosenbergerC, ScholzeCK, HorstrupJH, WarneckeC, MandriotaS, BechmannI, FreiUA, PughCW, RatcliffePJ, BachmannS, MaxwellPH, EckardtKU. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J, 17:271–273. 2003.
342.
WilsonWJ, PoellingerL. The dietary flavonoid quercetin modulates HIF-1 alpha activity in endothelial cells. Biochem Biophys Res Commun, 293:446–450. 2002.
343.
WittenL, SagerT, ThirstrupK, JohansenJL, LarsenDB, MontezinhoLP, MorkA. HIF prolyl hydroxylase inhibition augments dopamine release in the rat brain in vivo. J Neurosci Res, 87:1686–1694. 2009.
344.
XiaoXQ, LeeNT, CarlierPR, PangY, HanYF. Bis(7)-tacrine, a promising anti-Alzheimer's agent, reduces hydrogen peroxide-induced injury in rat pheochromocytoma cells: comparison with tacrine. Neurosci Lett, 290:197–200. 2000.
345.
Yogev-FalachM, AmitT, Bar-AMO, YoudimMBH. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J, 17:2325–2327. 2003.
346.
Yogev-FalachM, Bar-AmO, AmitT, WeinrebO, YoudimMB. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J, 20:2177–2179. 2006.
347.
YoudimMB. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti-Alzheimer drugs ladostigil and m30. Curr Alzheimer Res, 3:541–550. 2006.
348.
YoudimMB. Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotox Res, 14:45–56. 2008.
349.
YoudimMB, BuccafuscoJJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci, 26:27–35. 2005.
350.
YoudimMB, FridkinM, ZhengH. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J Neural Transmission, 111:1455–1471. 2004.
351.
YoudimMB, StephensonG, Ben ShacharD. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci, 1012:306–325. 2004.
352.
ZamanK, RyuH, HallD, O'DonovanK, LinKI, MillerMP, MarquisJC, BarabanJM, SemenzaGL, RatanRR. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci, 19:9821–9830. 1999.
353.
ZattaP, DragoD, BologninS, SensiSL. Alzheimer's disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci, 30:346–355. 2009.
354.
Zecca LM.B.H.Y, Riederer P, Connor JR, and Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci, 5:863–873. 2004.
355.
ZeccaL, StroppoloA, GattiA, TampelliniD, ToscaniM, GalloriniM, GiaveriG, ArosioP, SantambrogioP, FarielloRG, KaratekinE, KleinmanMH, TurroN, HornykiewiczO, ZuccaFA. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A, 101:9843–9838. 2004.
356.
ZhangB, TanakaJ, YangL, YangL, SakanakaM, HataR, MaedaN, MitsudaN. Protective effect of vitamin E against focal brain ischemia and neuronal death through induction of target genes of hypoxia-inducible factor-1. Neuroscience, 126:433–440. 2004.
357.
ZhengH, GalS, WeinerLM, Bar-AmO, WarshawskyA, FridkinM, YoudimMB. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem, 95:68–78. 2005.
358.
ZhengH, WeinerLM, Bar-AmO, EpsztejnS, CabantchikZI, WarshawskyA, YoudimMB, FridkinM. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem, 13:773–783. 2005.
359.
ZhengH, YoudimMB, WeinerLM, FridkinM. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem Pharmacol, 70:1642–1652. 2005.
360.
ZhongH, ChilesK, FeldserD, LaughnerE, HanrahanC, GeorgescuMM, SimonsJW, SemenzaGL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res, 60:1541–1545. 2000.
361.
ZhouYD, KimYP, LiXC, BaersonSR, AgarwalAK, HodgesTW, FerreiraD, NagleDG. Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts. J Nat Prod, 67:2063–2069. 2004.
362.
ZhuW, XieW, PanT, JankovicJ, LiJ, YoudimMB, LeW. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem, 105:1970–1978. 2008.
363.
ZhuW, XieW, PanT, XuP, FridkinM, ZhengH, JankovicJ, YoudimMB, LeW. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J, 21:3835–3844. 2007.
364.
ZielloJE, JovinIS, HuangY. Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med, 80:51–60. 2007.
365.
ZnamenskyV, AkamaKT, McEwenBS, MilnerTA. Estrogen levels regulate the subcellular distribution of phosphorylated Akt in hippocampal CA1 dendrites. J Neurosci, 23:2340–2347. 2003.